Ultragenyx Pharmaceutical
RARE
192 hedge funds and large institutions have $4.94B invested in Ultragenyx Pharmaceutical in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 65 increasing their positions, 66 reducing their positions, and 14 closing their positions.
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
85% more capital invested
Capital invested by funds: $2.67B → $4.94B (+$2.27B)
52% more call options, than puts
Call options by funds: $21.4M | Put options by funds: $14.1M
10% more funds holding
Funds holding: 174 → 192 (+18)
1.8% more ownership
Funds ownership: 104% → 105.8% (+1.8%)
2% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 66
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$196M |
| 2 |
ClearBridge Investments
New York
|
+$35.6M |
| 3 |
BlackRock
New York
|
+$23M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$18.2M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$64.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$16.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.8M |
| 5 |
Barclays
London,
United Kingdom
|
-$7.76M |
RARE Hedge Fund Activity: Q2 2020 in Review
192 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2020, worth a combined $4.94B — up 85% from $2.67B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RARE positions and 14 closed out — a net gain of 19 holders — while 65 added to existing stakes and 66 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $196M. The largest seller was Citadel Advisors, cutting an estimated $64.2M.
- 192 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2020, up from 174 in Q1 2020.
- Funds reported $4.94B of Ultragenyx Pharmaceutical stock for Q2 2020, up 85% quarter-over-quarter.
- 33 funds opened new Ultragenyx Pharmaceutical positions in Q2 2020 and 14 closed out, a net change of +19 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2020 was T. Rowe Price Associates, an estimated $196M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2020 was Citadel Advisors, an estimated $64.2M sold.
Based on aggregated 13F filings for Q2 2020.